✦ LIBER ✦

676 - Bispeciffic antibody MDX210 (FcγRI × HER-2/neu) in combination with G-CSF: Results of a phase I trial in patients with metastatic breast cancer

✍ Scribed by Th. Valerius; B. Stockmeyer; R. Repp; Y. Deo; H. van Oijk; J.G. van de Winkel; J.R. Kalden; M. Gramatzki

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical trial of the bispecific

✍ Repp, R; van Ojik, H H; Valerius, T; Groenewegen, G; Wieland, G; Oetzel, C; Stoc 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 197 KB

Clinical evaluation of the bispecific an

✍ H. H. van Ojik; R. Repp; Gerard Groenewegen; Thomas Valerius; Jan G. J. van de W 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 332 KB

A phase I study of a HER2/neu bispecific

✍ V. Pullarkat; Y. Deo; J. Link; L. Spears; V. Marty; R. Curnow; S. Groshen; C. Ge 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 365 KB

A Phase I/II Trial of Trastuzumab and Ge

✍ Stacy L. Moulder; Carlos L. Arteaga 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 440 KB

Pharmacokinetic–pharmacodynamic relation

✍ Lionel D Lewis; Bernard F Cole; Paul K Wallace; Jan L Fisher; Mary Waugh; Paul M 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 285 KB

5020 Pharmacokinetics (PK), safety, and

✍ H. Burris III; S. Vukelja; I. Krop; S. Modi; B. Klencke; S. Girish; M.X. Sliwkow 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB